Long term outcome in children affected by absence epilepsy with onset before the age of three years

Alberto Verrotti1, Cristina Olivieri, Sergio Agostinelli

  • 1Department of Pediatrics, University of Chieti, Chieti, Italy.

Epilepsy & Behavior : E&B
|January 14, 2011
PubMed

Insights

Early-onset absence epilepsy in children under 3 years old shows a favorable long-term outcome. Most children achieved seizure freedom and maintained normal cognitive functions, indicating a good prognosis.

Area of Science:

  • Neurology
  • Pediatric Epilepsy

Background:

  • Absence epilepsy is a common epilepsy syndrome in childhood.
  • The long-term prognosis of absence epilepsy presenting before 3 years of age is not well-defined.

Purpose of the Study:

  • To define the long-term clinical and neurocognitive outcome of absence epilepsy presenting before 3 years of age.

Main Methods:

  • Retrospective study of 40 children diagnosed with absence epilepsy before 3 years of age.
  • Data collected included personal and family history, follow-up duration, cognitive function, treatment, and outcome.
  • Diagnosis confirmed by EEG showing 3-Hz spike-wave complexes, normal neurological examination, and absence of other seizure types.

Main Results:

  • Forty children were included, with seizure onset between 24.1 and 36.0 months.
  • A family history of epilepsy was present in 28% and febrile seizures in 13%.
  • Valproic acid (VPA) was the primary treatment. At follow-up, 33 patients were seizure-free with normal EEGs.
  • 34 patients had normal IQs, while 6 had decreased IQs, often linked to uncontrolled seizures.

Conclusions:

  • Absence epilepsy presenting before 3 years of age has a good long-term clinical prognosis.
  • Neuropsychological outcomes were comparable to childhood epilepsy presenting after 3 years of age.
Abstract

Related Concept Videos

Epilepsy ll: Types01:22

Epilepsy ll: Types

Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures l: Introduction01:20

Seizures l: Introduction

Understanding seizures and epilepsy relies on key definitions that help in recognizing, classifying, and managing these disorders. These definitions provide a framework for recognizing, classifying, and managing seizure disorders.DefinitionsA seizure is a sudden, abnormal burst of electrical activity in the brain that can cause changes in awareness, movement, sensation, or behavior, depending on the area involved. Epilepsy is a chronic condition characterized by recurrent, unprovoked seizures,...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...